Characterization of the melatoninergic MT3 binding site on the NRH:quinone oxidoreductase 2 enzyme.

Abstract Melatonin acts through a series of molecular targets: the G-protein coupled receptors, MT 1 and MT 2 , and a third binding site, MT 3 , recently identified as the enzyme NRH:quinone oxydoreductase 2 (QR2). The relationship between the multiple physiological functions of melatonin and this enzyme remains unclear. Because of the relationship of QR2 with the redox status of cells, these studies could bring the first tools for a molecular rationale of the antioxidant effects of melatonin. In the present paper, we used a QR2-stably expressing cell line and hamster kidneys to compare the 2-[ 125 I]-iodomelatonin and 2-[ 125 I]-iodo-5-methoxycarbonylamino- N -acetyltryptamine binding data, and to characterize the MT 3 binding site. We designed and tested compounds from two distinct chemicals series in a displacement assay of the two MT 3 ligands, 2-[ 125 I]-iodomelatonin and 2-[ 125 I]-iodo-5-methoxycarbonylamino- N -acetyltryptamine from their cloned target. We also tested their ability to inhibit QR2 catalytic activity. These compounds were separated into two classes: those that bind within the catalytic site (and being inhibitors) and those that bind outside it (and therefore not being inhibitors). Compounds range from potent ligands ( K i = 1 nM) to potent inhibitors (14 nM), and include one compound [NMDPEF: N -[2-(2-methoxy-6H-dipyrido[2,3-a:3,2-e]pyrrolizin-11-yl)ethyl]-2-furamide] active on both parameters in the low nanomolar range. To dissect the physio-pathological pathways in which QR2, MT 3 and melatonin meet, one needs more compounds binding to MT 3 and/or inhibitors of QR2 enzymatic activity. The compounds described in the present paper are new tools for such a task.